Index by author

March 2017; volume 2, issue 1

A

  1. Ansaloni, Silvia

    1. Martoni, Andrea A et al "Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study." ESMO Open 2.1 (2017): e000116. Web. 21 Aug. 2017.

  2. Aprile, Giuseppe

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

  3. Arnoldi, Ermenegildo

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

  4. Aschele, Carlo

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

  5. Azambuja, Evandro de

    1. Maurer, Christian, Samuel Martel, and Evandro de Azambuja. "Male breast cancer: finding the way in this uncommon path." ESMO Open 2.1 (2017): e000169. Web. 21 Aug. 2017.

B

  1. Baba, Hideo

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  2. Banerjee, Susana

    1. Dolly, Saoirse O et al "Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy." ESMO Open 2.1 (2017): e000101. Web. 21 Aug. 2017.

  3. Barrueco, José

    1. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

  4. Beretta, Giordano D

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

  5. Bhattacharjee, Atanu

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  6. Boku, Narikazu

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

C

  1. Caglevic, Christian

    1. Thungappa, Satheesh et al "Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…." ESMO Open 2.1 (2017): e000162. Web. 21 Aug. 2017.

  2. Carnaghi, Carlo

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

  3. Cervantes, Andrés

    1. Cervantes, Andrés, and María José Terol. "In the literature: February 2017." ESMO Open 2.1 (2017): e000171. Web. 21 Aug. 2017.

  4. Chan, Anthony TC

    1. Chan, Juliana CN, and Anthony TC Chan. "Biologics and biosimilars: what, why and how?." ESMO Open 2.1 (2017): e000180. Web. 21 Aug. 2017.

  5. Chan, Juliana CN

    1. Chan, Juliana CN, and Anthony TC Chan. "Biologics and biosimilars: what, why and how?." ESMO Open 2.1 (2017): e000180. Web. 21 Aug. 2017.

  6. Chandrasekharan, Arun

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  7. Cheng, Ann-Lii

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  8. Chouaki, Nadia

    1. Garrido, Pilar et al "Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup." ESMO Open 2.1 (2017): e000141. Web. 21 Aug. 2017.

  9. Choughule, Anuradha Bharat

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  10. Cosimelli, Maurizio

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

D

  1. Degli Esposti, Claudia

    1. Martoni, Andrea A et al "Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study." ESMO Open 2.1 (2017): e000116. Web. 21 Aug. 2017.

  2. Della-Pepa, Chiara

    1. Dolly, Saoirse O et al "Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy." ESMO Open 2.1 (2017): e000101. Web. 21 Aug. 2017.

  3. Dolly, Saoirse O

    1. Dolly, Saoirse O et al "Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy." ESMO Open 2.1 (2017): e000101. Web. 21 Aug. 2017.

E

  1. Egawa, Shinichi

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

F

  1. Ferri, Jose

    1. Thungappa, Satheesh et al "Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…." ESMO Open 2.1 (2017): e000162. Web. 21 Aug. 2017.

  2. Funakoshi, Akihiro

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  3. Furuse, Junji

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

G

  1. Gann, Claudia-Nanette

    1. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

  2. Garrido, Pilar

    1. Garrido, Pilar et al "Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup." ESMO Open 2.1 (2017): e000141. Web. 21 Aug. 2017.

  3. Gaschler-Markefski, Birgit

    1. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

  4. Giraud, Philippe

    1. Garrido, Pilar et al "Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup." ESMO Open 2.1 (2017): e000141. Web. 21 Aug. 2017.

  5. Goel, Alok

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  6. Gottfried, Maya

    1. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

  7. Goud, Supriya

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

H

  1. Hagiwara, Yasuhiro

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  2. Hanna, Nasser H

    1. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

  3. Hashida, Hiroki

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  4. Hashimoto, Kazuki

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  5. Hatachi, Yukimasa

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  6. Hatori, Takashi

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  7. Hattori, Takayuki

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  8. Hayashi, Hidetoshi

    1. Kato, Ryoji et al "Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab." ESMO Open 2.1 (2017): e000145. Web. 21 Aug. 2017.

  9. Hazell, Steve

    1. Dolly, Saoirse O et al "Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy." ESMO Open 2.1 (2017): e000101. Web. 21 Aug. 2017.

  10. Heymach, John V

    1. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

  11. Hohokabe, Eri

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

I

  1. Ichikawa, Chihiro

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  2. Imagumbai, Toshiyuki

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  3. Imai, Yukihiro

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  4. Ioka, Tatsuya

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  5. Iwamoto, Shigeyoshi

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

J

  1. Janu, Amit

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  2. Joshi, Amit

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

K

  1. Kaihara, Satoshi

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  2. Kaiser, Rolf

    1. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

  3. Karpe, Ashay

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  4. Kato, Hironori

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  5. Kato, Ryoji

    1. Kato, Ryoji et al "Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab." ESMO Open 2.1 (2017): e000145. Web. 21 Aug. 2017.

  6. Kato, Takeshi

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  7. Kaye, Stanley B

    1. Dolly, Saoirse O et al "Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy." ESMO Open 2.1 (2017): e000101. Web. 21 Aug. 2017.

  8. Khakoo, Shelize

    1. Dolly, Saoirse O et al "Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy." ESMO Open 2.1 (2017): e000101. Web. 21 Aug. 2017.

  9. Kihara, Kiyohiro

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  10. Kikawa, Yuichiro

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  11. Kobayashi, Hiroyuki

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  12. Kokubo, Masaki

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  13. Komatsu, Yoshito

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  14. Kondo, Masato

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  15. Kosaka, Yasuhiro

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  16. Kotaka, Masahito

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  17. Kotake, Takeshi

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  18. Kumar, Rajiv

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

L

  1. Lelli, Giorgio

    1. Martoni, Andrea A et al "Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study." ESMO Open 2.1 (2017): e000116. Web. 21 Aug. 2017.

M

  1. Mahajan, Abhishek

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  2. Maiello, Evaristo

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

  3. Martel, Samuel

    1. Maurer, Christian, Samuel Martel, and Evandro de Azambuja. "Male breast cancer: finding the way in this uncommon path." ESMO Open 2.1 (2017): e000169. Web. 21 Aug. 2017.

  4. Martoni, Andrea A

    1. Martoni, Andrea A et al "Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study." ESMO Open 2.1 (2017): e000116. Web. 21 Aug. 2017.

  5. Matsumoto, Hiroshi

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  6. Maurer, Christian

    1. Maurer, Christian, Samuel Martel, and Evandro de Azambuja. "Male breast cancer: finding the way in this uncommon path." ESMO Open 2.1 (2017): e000169. Web. 21 Aug. 2017.

  7. Mellemgaard, Anders

    1. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

  8. Melotti, Barbara

    1. Martoni, Andrea A et al "Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study." ESMO Open 2.1 (2017): e000116. Web. 21 Aug. 2017.

  9. Migali, Cristina

    1. Dolly, Saoirse O et al "Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy." ESMO Open 2.1 (2017): e000101. Web. 21 Aug. 2017.

  10. Miki, Akira

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  11. Mishima, Hideyuki

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  12. Mizumoto, Kazuhiro

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  13. More, Sucheta

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  14. Morita, Satoshi

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  15. Muro, Kei

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  16. Murotani, Kenta

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  17. Mutri, Vita

    1. Martoni, Andrea A et al "Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study." ESMO Open 2.1 (2017): e000116. Web. 21 Aug. 2017.

N

  1. Nakagawa, Kazuhiko

    1. Kato, Ryoji et al "Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab." ESMO Open 2.1 (2017): e000145. Web. 21 Aug. 2017.

  2. Nakamura, Masato

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  3. Narukami, Ryo

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  4. Normanno, Nicola

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

  5. Noronha, Vanita

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  6. Novello, Silvia

    1. Garrido, Pilar et al "Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup." ESMO Open 2.1 (2017): e000141. Web. 21 Aug. 2017.
    2. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

O

  1. Ogura, Kengo

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  2. Ohashi, Yasuo

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  3. Ohkawa, Shinichi

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  4. Okita, Yoshihiro

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  5. Okusaka, Takuji

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

P

  1. Pande, Nikhil

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  2. Pannuti, Franco

    1. Martoni, Andrea A et al "Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study." ESMO Open 2.1 (2017): e000116. Web. 21 Aug. 2017.

  3. Passiglia, Francesco

    1. Thungappa, Satheesh et al "Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…." ESMO Open 2.1 (2017): e000162. Web. 21 Aug. 2017.

  4. Patil, Vijay Maruti

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  5. Piva, Erico

    1. Martoni, Andrea A et al "Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study." ESMO Open 2.1 (2017): e000116. Web. 21 Aug. 2017.

  6. Prabhash, Kumar

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  7. Purandare, Nilendu

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

R

  1. Raez, Luis

    1. Thungappa, Satheesh et al "Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…." ESMO Open 2.1 (2017): e000162. Web. 21 Aug. 2017.

  2. Ramaswamy, Anant

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  3. Reck, Martin

    1. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

  4. Ricardi, Umberto

    1. Garrido, Pilar et al "Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup." ESMO Open 2.1 (2017): e000141. Web. 21 Aug. 2017.

  5. Rolfo, Christian

    1. Thungappa, Satheesh et al "Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…." ESMO Open 2.1 (2017): e000162. Web. 21 Aug. 2017.

S

  1. Sakata, Yuh

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  2. Salvatore, Lisa

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

  3. Sasaki, Yasutsuna

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  4. Satake, Hironaga

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  5. Sato, Atsushi

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  6. Satoh, Taroh

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  7. Sciallero, Stefania

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

  8. Serke, Monika

    1. Garrido, Pilar et al "Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup." ESMO Open 2.1 (2017): e000141. Web. 21 Aug. 2017.

  9. Shimada, Ken

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  10. Shimada, Yasuhiro

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  11. Sikken, Patricia

    1. Gaschler-Markefski, Birgit et al "Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer." ESMO Open 2.1 (2017): e000102. Web. 21 Aug. 2017.

  12. Sobrero, Alberto

    1. Sobrero, Alberto. "The hard road to ranking the clinical benefit of antineoplastic agents: ESMO Award 2016 presentation." ESMO Open 2.1 (2017): e000157. Web. 21 Aug. 2017.

  13. Soldatenkova, Victoria

    1. Garrido, Pilar et al "Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup." ESMO Open 2.1 (2017): e000141. Web. 21 Aug. 2017.

  14. Strocchi, Elena

    1. Martoni, Andrea A et al "Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study." ESMO Open 2.1 (2017): e000116. Web. 21 Aug. 2017.

  15. Sugihara, Kenichi

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

T

  1. Takahari, Daisuke

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  2. Takahashi, Keiichi

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  3. Takebe, Sayaka

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  4. Takeda, Masayuki

    1. Kato, Ryoji et al "Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab." ESMO Open 2.1 (2017): e000145. Web. 21 Aug. 2017.

  5. Talreja, Vikas

    1. Patil, Vijay Maruti et al "Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma." ESMO Open 2.1 (2017): e000168. Web. 21 Aug. 2017.

  6. Tanaka, Kaoru

    1. Kato, Ryoji et al "Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab." ESMO Open 2.1 (2017): e000145. Web. 21 Aug. 2017.

  7. Tanaka, Masao

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  8. Tanizaki, Junko

    1. Kato, Ryoji et al "Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab." ESMO Open 2.1 (2017): e000145. Web. 21 Aug. 2017.

  9. Terol, María José

    1. Cervantes, Andrés, and María José Terol. "In the literature: February 2017." ESMO Open 2.1 (2017): e000171. Web. 21 Aug. 2017.

  10. Thungappa, Satheesh

    1. Thungappa, Satheesh et al "Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…." ESMO Open 2.1 (2017): e000162. Web. 21 Aug. 2017.

  11. Tsuji, Akihito

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  12. Tunariu, Nina

    1. Dolly, Saoirse O et al "Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy." ESMO Open 2.1 (2017): e000101. Web. 21 Aug. 2017.

U

  1. Ueki, Kazuhiro

    1. Kikawa, Yuichiro et al "Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey." ESMO Open 2.1 (2017): e000161. Web. 21 Aug. 2017.

  2. Ueno, Hideki

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

V

  1. Vallejo, Carmen

    1. Garrido, Pilar et al "Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup." ESMO Open 2.1 (2017): e000141. Web. 21 Aug. 2017.

  2. Valvo, Francesca

    1. Salvatore, Lisa et al "Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)." ESMO Open 2.1 (2017): e000147. Web. 21 Aug. 2017.

  3. Visseren-Grul, Carla

    1. Garrido, Pilar et al "Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup." ESMO Open 2.1 (2017): e000141. Web. 21 Aug. 2017.

W

  1. Watanabe, Masahiko

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

Y

  1. Yamada, Yasuhide

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  2. Yamaguchi, Taketo

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  3. Yamao, Kenji

    1. Hagiwara, Yasuhiro et al "Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study." ESMO Open 2.1 (2017): e000151. Web. 21 Aug. 2017.

  4. Yasui, Hisateru

    1. Satake, Hironaga et al "Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)." ESMO Open 2.1 (2017): e000130. Web. 21 Aug. 2017.

  5. Yoshida, Kazuhiro

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.

  6. Yoshida, Motoki

    1. Baba, Hideo et al "S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study." ESMO Open 2.1 (2017): e000135. Web. 21 Aug. 2017.
Back to top

In this issue

Jump to